FDA ApprovedUnited States
New Infusion Treatment for Thyroid Eye Disease
Lumvoa (veligrotug-vvze) for thyroid eye disease (active and chronic)
The FDA labelled an intravenous IGF-1R monoclonal antibody for thyroid eye disease regardless of disease activity or duration on 26 June 2026. The…
The FDA labelled an intravenous IGF-1R monoclonal antibody for thyroid eye disease regardless of disease…